Completed PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT04333420

Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia (PANAMO)

A Pragmatic Adaptive Randomized, Controlled Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia

Sponsor: InflaRx GmbH

Conditions Severe COVID-19 Pneumonia

Interventions BSC IFX-1 + BSC IFX-1 + SOC Placebo + SOC

Updated 2 times since 2024 Last updated: May 25, 2023 Started: Mar 31, 2020 Primary completion: Oct 31, 2021 Completion: Dec 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Severe COVID-19 Pneumonia, this trial is completed. The trial is conducted by InflaRx GmbH and has accumulated 2 data snapshots since 2020. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3

First recorded

Mar 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

InflaRx GmbH

Data source: InflaRx GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Aalst, Belgium , Amsterdam, Netherlands , Augsburg, Germany , Barnaul, Russia , Belo Horizonte, Brazil , Berlin, Germany , Brussels, Belgium , Callao, Peru , Campinas, Brazil and 32 more locations